Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STR-P004 in Relapsed/Refractory CD19-Positive B-Lymphocytic Non-Hodgkin's Lymphoma
NCT07003178Phase 1Not yet recruiting
- Sponsor
- Starna Therapeutics
- Start
- Jun 2025
- Primary completion
- Apr 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of STR-P004 in B-cell non-Hodgkin lymphoma (5 arms), sponsored by Starna Therapeutics. Primary endpoint: Incidence of Dose-Limiting Toxicity at 24 months. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
STR-P004
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT07003178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07003178.